VBI Vaccines to Present at the H.C. Wainwright 21st Annual Global Investment Conference
September 05 2019 - 8:00AM
VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage
biopharmaceutical company developing next-generation infectious
disease and immuno-oncology vaccines, today announced that Jeff
Baxter, President and CEO, will present at the H.C. Wainwright 21st
Annual Global Investment Conference in New York City on Tuesday,
September 10, 2019, at 8:20 AM ET.
-
Event: H.C. Wainwright 21st
Annual Global Investment Conference
-
Date: Tuesday, September 10, 2019
-
Time: 8:20 – 8:45 AM
ET -
Webcast:
http://wsw.com/webcast/hcw5/vbiv/
A live webcast of the presentation may also be
accessed by visiting the Investors page of VBI’s website at
www.vbivaccines.com.
About VBI Vaccines
Inc.
VBI Vaccines Inc. (Nasdaq: VBIV) is a
commercial-stage biopharmaceutical company developing a next
generation of vaccines to address unmet needs in infectious disease
and immuno-oncology. VBI is advancing the prevention and treatment
of hepatitis B, with the only commercially-approved trivalent
hepatitis B vaccine, Sci-B-Vac®, which is approved for use in
Israel and 10 other countries and is currently in a Phase 3 program
in the U.S., Europe, and Canada, and with an immunotherapeutic in
development for a functional cure for chronic hepatitis B. VBI’s
eVLP Platform technology allows for the development of enveloped
virus-like particle (eVLP) vaccines that closely mimic the target
virus to elicit a potent immune response. Integrating its
cytomegalovirus (CMV) expertise with the eVLP platform technology,
VBI’s lead eVLP program candidates include a prophylactic CMV
vaccine candidate and a glioblastoma (GBM) vaccine
immunotherapeutic candidate. VBI is headquartered in Cambridge, MA
with research operations in Ottawa, Canada and research and
manufacturing facilities in Rehovot, Israel.
Website Home:
http://www.vbivaccines.com/
News and Insights:
http://www.vbivaccines.com/wire/
Investors:
http://www.vbivaccines.com/investors/
Cautionary Statement on
Forward-looking Information
Certain statements in this press release that
are forward-looking and not statements of historical fact are
forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995
and are forward-looking information within the meaning of Canadian
securities laws (collectively, “forward-looking statements”). The
company cautions that such statements involve risks and
uncertainties that may materially affect the company's results of
operations. Such forward-looking statements are based on the
beliefs of management as well as assumptions made by and
information currently available to management. Actual results could
differ materially from those contemplated by the forward-looking
statements as a result of certain factors, including but not
limited to the ability to establish that potential products are
efficacious or safe in preclinical or clinical trials; the ability
to establish or maintain collaborations on the development of
therapeutic candidates; the ability to obtain appropriate or
necessary governmental approvals to market potential products; the
ability to obtain future funding for developmental products and
working capital and to obtain such funding on commercially
reasonable terms; the company's ability to manufacture product
candidates on a commercial scale or in collaborations with third
parties; changes in the size and nature of competitors; the ability
to retain key executives and scientists; and the ability to secure
and enforce legal rights related to the company's products. A
discussion of these and other factors, including risks and
uncertainties with respect to the company, is set forth in the
Company's filings with the Securities and Exchange Commission and
the Canadian securities authorities, including its Annual Report on
Form 10-K filed with the Securities and Exchange Commission on
February 25, 2019, and filed with the Canadian security authorities
at sedar.com on February 25, 2019, as may be supplemented or
amended by the Company's Quarterly Reports on Form 10-Q. Given
these risks, uncertainties and factors, you are cautioned not to
place undue reliance on such forward-looking statements, which are
qualified in their entirety by this cautionary statement. All such
forward-looking statements made herein are based on our current
expectations and we undertake no duty or obligation to update or
revise any forward-looking statements for any reason, except as
required by law.
VBI
Contact
Nicole AndersonAssociate, Corporate
CommunicationsPhone: (617) 830-3031 x124Email:
info@vbivaccines.com
VBI Investor
Contact
Nell BeattieChief Business OfficerEmail:
ir@vbivaccines.com
VBI Media
Contact
Burns McClellan, Inc.Robert Flamm, Ph.D.Phone:
(212) 213-0006Email: rflamm@burnsmc.com
VBI Vaccines (NASDAQ:VBIV)
Historical Stock Chart
From Mar 2024 to Apr 2024
VBI Vaccines (NASDAQ:VBIV)
Historical Stock Chart
From Apr 2023 to Apr 2024